North America Alpha-Glucosidase Inhibitors Market Size
| Study Period | 2019- 2029 |
| Base Year For Estimation | 2023 |
| Forecast Data Period | 2024 - 2029 |
| Market Size (2024) | USD 0.28 Billion |
| Market Size (2029) | USD 0.32 Billion |
| CAGR (2024 - 2029) | 2.50 % |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
North America Alpha-Glucosidase Inhibitors Market Analysis
The North America Alpha-Glucosidase Inhibitors Market size is estimated at USD 0.28 billion in 2024, and is expected to reach USD 0.32 billion by 2029, growing at a CAGR of 2.5% during the forecast period (2024-2029).
In North America, the United States has the highest number of COVID cases with 82 million by April 2022, the country also registered the highest death rate. According to the Diabetes Voice article published in May 2020, close to 40,000 deaths are people with diabetes. In the North American region diabetes patients are more concerned about stocking up the monitoring and managing devices due to this the market increased during these years.
The North American region has witnessed an astounding increase in the prevalence of diabetes, in recent years. In developed countries, such as the United States and Canada, the rate of diabetes is at an all-time high, mainly due to lifestyle changes. Diabetes is associated with many health complications. According to FDA, comparing the population with and without diabetes, those with diabetes have a 300% increased risk of being hospitalized and thus incur more healthcare expenses compared to non-diabetic people. Patients with Type 2 diabetes require many corrections throughout the day for maintaining nominal blood glucose levels, such as the administration of additional insulin or ingestion of additional carbohydrates.
The World Health Assembly agreed on a Resolution to strengthen diabetes prevention and control in May 2021. It recommends actions such as increasing access to diabetes medicines and health products and assessing the feasibility and potential value of establishing a web-based tool to share information relevant to market transparency for diabetes medicines and health products.
The FDA approves AGIs for the treatment of type 2 diabetes mellitus. They have shown some benefits in type 1 diabetes mellitus and gestational diabetes mellitus but are not FDA-approved for these indications. Acarbose has been shown to decrease body weight in a worldwide observational study. AGIs are particularly useful for reducing postprandial hyperglycemia. They modestly decrease glycosylated hemoglobin levels and also reduce postprandial insulin concentration. Compared with oral antihyperglycemic drugs, they also reduce glucose variability throughout the day. They, however, do not affect fasting insulin and serum triglyceride concentrations.
This is driving the demand for Alpha-Glucosidase Inhibitors in North America, thereby driving the market in focus during the forecast period.
North America Alpha-Glucosidase Inhibitors Market Trends
Rising Diabetes Prevalence in North America Region
According to the National Diabetes Statistics Report 2022, approximately 37.5 million people, or approximately 11.3% of the US population, had diabetes. People who are overweight are more likely to develop prediabetes, which can progress to type-2 diabetes, putting them at risk for complications, acute and long-term complications, and death. Obesity, an unhealthy diet, and a sedentary lifestyle are all contributing to an increase in newly diagnosed type-1 and type-2 diabetes cases. The increased prevalence of diabetic patients and global healthcare expenditure are indicators of a greater proclivity for diabetic drugs. Type-2 diabetes (T2D) is becoming more common and is linked to an increased risk of cardiovascular and renal disease. Meglitinides are oral medications used to treat type-2 diabetes in conjunction with lifestyle changes. They work by stimulating insulin release from pancreatic beta cells, which lowers blood glucose levels.
The North American region has witnessed an astounding increase in the prevalence of diabetes in recent years. In developed countries, such as the United States and Canada, the rate of diabetes is at an all-time high, mainly due to lifestyle changes. Diabetes is associated with many health complications. Comparing the population with and without diabetes, those with diabetes have a 300% increased risk of being hospitalized and thus incur more healthcare expenses than non-diabetic people. Patients with type-2 diabetes require many corrections throughout the day to maintain nominal blood glucose levels, such as the administration of additional insulin or the ingestion of additional carbohydrates.
The United States is Expected to Dominate North America Alpha-Glucosidase Inhibitors Market.
Acarbose (Precose), voglibose, and miglitol (Glyset) are medications in the alpha-glucosidase inhibitors class of drugs. These drugs help keep the amount of glucose in the blood from rising too fast after meals. Alpha-glucosidase inhibitors help lower postprandial diabetes. These medications reduce the levels of glycosylated hemoglobin and lower the concentration of postprandial insulin. Regulation of post-meal hyperglycemia is vital, as it is associated with the development of complications and also increases the risk of heart problems.
Type-2 diabetes is increasingly prevalent and associated with an increased risk for cardiovascular and renal disease. Alpha-glucosidase inhibitors may also be used in patients with impaired glucose tolerance to delay the occurrence of type-2 diabetes mellitus in these patients. They are particularly useful for patients who are at risk of hypoglycemia or lactic acidosis and are not suitable candidates for other antidiabetic drugs such as sulfonylureas and metformin. Alpha-glucosidase inhibitors are FDA-approved for the treatment of type-2 diabetes mellitus.
In April 2021, WHO launched the Global Diabetes Compact, a global initiative aiming for sustained improvements in diabetes prevention and care, with a particular focus on supporting low and middle-income countries. The Compact is bringing together national governments, UN organizations, nongovernmental organizations, private sector entities, academic institutions, philanthropic foundations, people living with diabetes, and international donors to work on a shared vision of reducing the risk of diabetes and ensuring that all people who are diagnosed with diabetes have access to equitable, comprehensive, affordable, and quality treatment and care.
Owing to the aforementioned factors, the market is expected to grow during the forecast period.
North America Alpha-Glucosidase Inhibitors Industry Overview
The North American alpha-glucosidase inhibitors market studied is highly fragmented into many manufacturers like Bayer, SunPharma, Pfizer, and Takeda, holding a presence in all regions.
North America Alpha-Glucosidase Inhibitors Market Leaders
-
Takeda
-
Pfizer
-
Bayer
-
Sunpharma
-
Glenmark
*Disclaimer: Major Players sorted in no particular order
North America Alpha-Glucosidase Inhibitors Market News
- April 2023: A study was planned to move towards drug repurposing by utilizing Food and Drug Administration (FDA)-approved drugs against glucosidase and investigating the molecular mechanisms. The target protein was refined and optimized by introducing missing residues and minimizing clashes to find the potential inhibitor against glucosidase.
- July 2022: The drug pricing regulator, the National Pharmaceutical Pricing Authority (NPPA), fixed the prices of 84 drug formulations, including those used for the treatment of diabetes. According to the order, a single tablet of Voglibose was expected to cost Rs 10.47 (USD 0.13), excluding GST.
North America Alpha-Glucosidase Inhibitors Market Report - Table of Contents
1. INTRODUCTION
- 1.1 Study Assumptions and Market Definition
- 1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
- 4.1 Market Overview
- 4.2 Drivers
- 4.3 Restraints
-
4.4 Porter's Five Forces Analysis
- 4.4.1 Bargaining Power of Suppliers
- 4.4.2 Bargaining Power of Consumers
- 4.4.3 Threat of New Entrants
- 4.4.4 Threat of Substitute Products and Services
- 4.4.5 Intensity of Competitive Rivalry
5. MARKET INDICATORS
- 5.1 Type-1 Diabetes Population
- 5.2 Type-2 Diabetes Population
6. COMPETITIVE LANDSCAPE
-
6.1 Company Profiles
- 6.1.1 Pfizer
- 6.1.2 Glenmark pharma
- 6.1.3 Sun pharma
- 6.1.4 Torrent
- 6.1.5 Unichem
- 6.1.6 Hexalag
- *List Not Exhaustive
- 6.2 Company Share Analysis
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
** Subject To AvailablityNorth America Alpha-Glucosidase Inhibitors Industry Segmentation
Type-2 diabetes is treated with medications called alpha-glucosidase inhibitors. This family of pharmaceuticals consists of two drugs: acarbose (Precose) and miglitol (Glyset). The North America alpha-glucosidase inhibitors market is segmented by geography (United States, Canada, and the Rest of North America). The report offers the value (in USD) and volume (in units) for the above segments. This report will provide a segment-wise breakdown (value and volume) for all the countries covered under the table of contents.
North America Alpha-Glucosidase Inhibitors Market Research FAQs
How big is the North America Alpha-Glucosidase Inhibitors Market?
The North America Alpha-Glucosidase Inhibitors Market size is expected to reach USD 0.28 billion in 2024 and grow at a CAGR of 2.5% to reach USD 0.32 billion by 2029.
What is the current North America Alpha-Glucosidase Inhibitors Market size?
In 2024, the North America Alpha-Glucosidase Inhibitors Market size is expected to reach USD 0.28 billion.
Who are the key players in North America Alpha-Glucosidase Inhibitors Market?
Takeda, Pfizer, Bayer, Sunpharma and Glenmark are the major companies operating in the North America Alpha-Glucosidase Inhibitors Market.
What years does this North America Alpha-Glucosidase Inhibitors Market cover, and what was the market size in 2023?
In 2023, the North America Alpha-Glucosidase Inhibitors Market size was estimated at USD 0.27 billion. The report covers the North America Alpha-Glucosidase Inhibitors Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the North America Alpha-Glucosidase Inhibitors Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
North America Alpha-Glucosidase Inhibitors Industry Report
Statistics for the 2024 North America Alpha-Glucosidase Inhibitors market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. North America Alpha-Glucosidase Inhibitors analysis includes a market forecast outlook 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
